BerGenBio ASA reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was NOK 84.07 million compared to NOK 88.86 million a year ago. Basic loss per share from continuing operations was NOK 0.95 compared to NOK 1.02 a year ago.
For the six months, net loss was NOK 165.14 million compared to NOK 170.1 million a year ago. Basic loss per share from continuing operations was NOK 1.86 compared to NOK 1.94 a year ago.